ClinicalTrials.gg
CompletedNCT00409578Updated Apr 19, 2011Results posted

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

A Phase 2 interventional study of Placebo and Aliskiren 300 mg in Post Acute Coronary Syndrome and Myocardial Ischemia, sponsored by Novartis. Completed at 11 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-19.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,101
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 218 studies in Myocardial Ischemia with a site in United States — 23 open to participants now, 26 under way, none of them phase 3. Myocardial Ischemia · United States.

Enrollment
31st of 150
1,101 · median 87
Started
2007
with 7 others
Phase 2
27 of 218
2 open now
Registered
42nd of 218
by date

Among the 218 studies in Myocardial Ischemia with a site in United States, this one is the 31st largest by enrollment of the 150 interventional ones that give a count, is one of 8 that started in 2007, is one of 27 in phase 2, and was the 42nd registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

23 of the 218 studies in Myocardial Ischemia with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies in Myocardial Ischemia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to test the hypothesis that the inhibition of the renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan or the renin antagonist aliskiren will improve ventricular hemodynamics, as reflected by a greater reduction in levels of N-terminal proB-type natriuretic peptide (NT-proBNP) compared to placebo in subjects stabilized following acute coronary syndrome (ACS) who are determined to be at high risk due to an elevated concentration of natriuretic peptides.

03

Conditions studied

  • Post Acute Coronary Syndrome
  • Myocardial Ischemia

Keywords

  • Post acute coronary syndrome
  • Acute
  • coronary syndrome
  • B-type natriuretic peptide
  • N-terminal
  • pro-B-type natriuretic peptide
  • myocardial infarctions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients 18 years old or older
  • Subjects who are hospitalized for ischemic chest discomfort at rest lasting at least 10 minutes and consistent with cardiac ischemia
  • Final diagnosis of acute coronary syndrome
  • Elevated concentrations of natriuretic peptide 3-10 days after admission for their qualifying acute coronary syndrome event

Exclusion criteria

Exclusion Criteria:

  • Known or suspected , including history of allergy or to angiotensin receptor blockers (ARBs), renin antagonists, or to drugs with similar chemical structures.
  • Presence of clinically overt heart failure
  • Known evidence of left ventricular systolic dysfunction
  • Percutaneous coronary intervention (PCI) less than 24 hours before randomization.
  • Patients on chronic ACEI or ARB therapy for whom therapy with an ACEI or ARB is clinically required with no reasonable alternative therapy available.

Other protocol-defined inclusion/exclusion criteria applied to the study.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,101 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo tablets and capsules

    Drug: Placebo

  • Experimental
    Aliskiren 300 mg

    Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.

    Drug: Aliskiren 300 mg

  • Experimental
    Valsartan 320 mg

    Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.

    Drug: Valsartan 320 mg

  • Experimental
    Aliskiren/valsartan 300/320 mg

    Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.

    Drug: Aliskiren/valsartan 300/320 mg

Interventions

  • DrugPlacebo

    Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.

  • DrugAliskirenStudies of AliskirenAliskiren pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.

  • DrugValsartanStudies of ValsartanValsartan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.

  • DrugAliskiren/valsartan 300/320 mg

    Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 8

    Blood samples for the measurement of NT-proBNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change From Baseline in B-type Natriuretic Peptide (BNP) at Week 8

    Blood samples for the measurement of BNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.

    Time frame: Baseline to Week 8

  2. Percentage of Patients With a Cardiac Event

    A cardiac event was defined as at least one of the following events: Cardiovascular death, recurrent myocardial infarction (MI), or hospitalization for congestive heart failure (CHF), all to be confirmed by adjudication.

    Time frame: Baseline to Week 8

  3. Percentage of Patients With a Composite Clinical-biochemical Event

    A composite clinical-biochemical event was defined as at least one of the following events: cardiovascular death confirmed by adjudication, recurrent MI confirmed by adjudication, hospitalization for CHF confirmed by adjudication, and/or NT-proBNP =\> 200 pg/mL.

    Time frame: Baseline to Week 8

07

Results

Posted Feb 2, 2011

Participant flow

Participant flow — Overall Study
MilestonePlaceboAliskiren 300 mgValsartan 320 mgAliskiren/Valsartan 300/320 mg
Started280271269281
Completed228201215214
Not completed52705467
Withdrew: Adverse event27372533
Withdrew: Abnormal laboratory value(s)2224
Withdrew: Lack of efficacy0002
Withdrew: Subject no longer requires study drug0001
Withdrew: Withdrawal by subject8151617
Withdrew: Lost to follow-up2022
Withdrew: Administrative problems8924
Withdrew: Death2442
Withdrew: Protocol violation3231
Withdrew: Missing0101

Outcome measures

PrimaryChange From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 8

Blood samples for the measurement of NT-proBNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.

Time frame:
Baseline to Week 8
Reported as:
Geometric mean · pg/mL
Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 8
pg/mLPlaceboAliskiren 300 mgValsartan 320 mgAliskiren/Valsartan 300/320 mg
Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 80.582 (0.502 to 0.676)0.563 (0.483 to 0.656)0.614 (0.526 to 0.716)0.635 (0.548 to 0.737)
SecondaryChange From Baseline in B-type Natriuretic Peptide (BNP) at Week 8

Blood samples for the measurement of BNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.

Time frame:
Baseline to Week 8
Reported as:
Geometric mean · pg/mL
Change From Baseline in B-type Natriuretic Peptide (BNP) at Week 8
pg/mLPlaceboAliskiren 300 mgValsartan 320 mgAliskiren/Valsartan 300/320 mg
Change From Baseline in B-type Natriuretic Peptide (BNP) at Week 80.642 (0.535 to 0.770)0.597 (0.495 to 0.720)0.670 (0.554 to 0.810)0.682 (0.568 to 0.818)
SecondaryPercentage of Patients With a Cardiac Event

A cardiac event was defined as at least one of the following events: Cardiovascular death, recurrent myocardial infarction (MI), or hospitalization for congestive heart failure (CHF), all to be confirmed by adjudication.

Time frame:
Baseline to Week 8
Reported as:
Number · Percentage of patients
Percentage of Patients With a Cardiac Event
Percentage of patientsPlaceboAliskiren 300 mgValsartan 320 mgAliskiren/Valsartan 300/320 mg
Percentage of Patients With a Cardiac Event2.94.94.94.0
SecondaryPercentage of Patients With a Composite Clinical-biochemical Event

A composite clinical-biochemical event was defined as at least one of the following events: cardiovascular death confirmed by adjudication, recurrent MI confirmed by adjudication, hospitalization for CHF confirmed by adjudication, and/or NT-proBNP =\> 200 pg/mL.

Time frame:
Baseline to Week 8
Reported as:
Number · Percentage of patients
Percentage of Patients With a Composite Clinical-biochemical Event
Percentage of patientsPlaceboAliskiren 300 mgValsartan 320 mgAliskiren/Valsartan 300/320 mg
Percentage of Patients With a Composite Clinical-biochemical Event79.573.577.275.2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—26/278 (9.4%)64/278 (23%)
Aliskiren 300 mg—39/264 (14.8%)61/264 (23.1%)
Valsartan 320 mg—33/268 (12.3%)51/268 (19%)
Aliskiren/Valsartan 300/320 mg—46/279 (16.5%)57/279 (20.4%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventPlaceboAliskiren 300 mgValsartan 320 mgAliskiren/Valsartan 300/320 mg
Non-cardiac chest painGeneral disorders2/2787/2642/2683/279
Angina pectorisCardiac disorders2/2785/2643/2686/279
Myocardial infarctionCardiac disorders1/2782/2640/2685/279
Acute myocardial infarctionCardiac disorders1/2784/2642/2680/279
Angina unstableCardiac disorders1/2782/2641/2684/279
Myocardial ischaemiaCardiac disorders0/2781/2641/2684/279
Acute coronary syndromeCardiac disorders0/2783/2641/2681/279
HypotensionVascular disorders0/2783/2640/2682/279
Cardiac failureCardiac disorders2/2781/2643/2682/279
PneumoniaInfections and infestations1/2780/2643/2681/279
Most frequent other events
Most frequent other events
EventPlaceboAliskiren 300 mgValsartan 320 mgAliskiren/Valsartan 300/320 mg
DizzinessNervous system disorders15/27823/26413/26819/279
HeadacheNervous system disorders18/27810/2647/26810/279
HyperkalaemiaMetabolism and nutrition disorders17/27816/26413/26813/279
Orthostatic hypotensionVascular disorders14/27816/26412/26813/279
Angina pectorisCardiac disorders13/2789/26414/2688/279

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboAliskiren 300 mgValsartan 320 mgAliskiren/Valsartan 300/320 mgTotal
Mean63 ± 11.863 ± 11.764 ± 11.663 ± 11.163 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAliskiren 300 mgValsartan 320 mgAliskiren/Valsartan 300/320 mgTotal
Female103867287348
Male177185197194753
08

Study locations

11 sites
  • Investigative Site
    Investigative Site, New Jersey, United States
  • Investigative Site
    Investigative Site, Belgium
  • Investigative Site
    Investigative Site, Canada
  • Investigative Site
    Investigative Site, Czech Republic
  • Investigative Site
    Investigative Site, Germany
  • Investigative Site
    Investigative Site, Hungary
  • Investigative Site
    Investigative Site, Netherlands
  • Investigative Site
    Investigative Site, Poland
  • Investigative Site
    Investigative Site, Russian Federation
  • Investigative Site
    Investigative Site, Spain
  • Investigative Site
    Investigative Site, Sweden
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2006
First posted
Dec 11, 2006
Start
Feb 2007
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Feb 2, 2011
Last update
Apr 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00409578
Lead sponsor
Novartis
Collaborators
The TIMI Study Group
First posted
Dec 11, 2006
Start date
Feb 2007
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Feb 2, 2011
Last update
Apr 19, 2011

Study contacts

Eugene Braunwald, MD
study chair · TIMI Study Group, Boston, MA
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aliskiren · Valsartan

Start the discussion